Mindpeak raises $15.3 million in Series A funding to accelerate development of AI-powered digital pathology

The funding strengthens the development pipeline for AI-based histopathology assessment products, supporting clinical laboratories and biopharmaceutical companies around the world.

HAMBURG, Germany–(BUSINESS WIRE)–Mindpeak, a leader in artificial intelligence-based pathology solutions, today announced that it has raised $15.3 million in a Series A financing round. The round was led by ZEISS Ventures and InnoVentureFund with participation from, among others. AI.FUND and the European Innovation Council Fund. While Mindpeak’s core business is cash flow positive, this new investment will enable the company to further expand the commercialization of its pioneering technologies in several geographic locations.

“With this new capital, we will accelerate the development and deployment of our AI solutions, providing pathologists and researchers with faster and more accurate diagnostic tools,” he said Felix FaberCEO of Mindpeak. “Our goal is to revolutionize cancer diagnosis and ultimately improve patient outcomes.”

Mindpeak’s AI algorithms were among the first to be implemented in routine clinical diagnostics in both the US and the EU. The company’s innovative solutions enable automated histological and immunohistochemical analysis of tissues, helping experts make more confident decisions. To date, the AI ​​solution has supported over 30,000 patient diagnoses. Biopharmaceutical companies are also using this artificial intelligence technology to predict the effectiveness of certain cancer therapy drugs and enable targeted treatments.

“Since its founding in 2018, Mindpeak has been developing cutting-edge solutions, establishing itself as an outstanding leader in the digital pathology market,” said Mike Gänßler, Investment Manager at ZEISS Ventures. “Both as an investor and a market partner, we are deeply convinced of Mindpeak’s promising future.”

Mindpeak recently expanded its product portfolio to include additional organs, biomarkers and dyes. Strategic partnerships with leading healthcare organizations such as Roche, along with positive regulatory developments, further strengthen the company’s position in the market.

“Mindpeak’s commitment to innovation in digital pathology has been evident through its rapid product development and growing market adoption,” said Gencer Sahin, Chief Investment Officer at IFB Innovationsstarter GmbH / InnoVentureFund. “This round of funding will further strengthen their position as a key player in the transformation of cancer diagnostics.”

About Mindpeak

Founded in 2018, Mindpeak is a global innovator of AI-powered digital pathology solutions. The company develops cutting-edge algorithms that support pathologists in routine diagnostics, focusing on automating tissue analysis for faster and more accurate results. The Mindpeak platform is designed to increase productivity and diagnostic confidence in clinical laboratories, helping to improve outcomes for cancer patients. For more information, please visit www.mindpeak.ai, Twitter and LinkedIn.

About ZEISS projects

ZEISS Ventures, the corporate capital company of the ZEISS Group, invests in and actively manages a portfolio of start-ups. Our goal is to invest in and collaborate with high-tech startups that extend beyond ZEISS’s core business and have the potential to disrupt and innovate existing technologies and business models. ZEISS Ventures aims to provide startups not only with the capital they need, but also with access to its resources, capabilities and global network as a deep tech corporation to support and accelerate their growth. More information can be found at www.zeiss.com/ventures.

About IFB Innovationsstarter / InnoVentureFund

InnoVentureFund invests in young innovative companies to strengthen the Hamburg startup scene and support startups in their further development. In cooperation with private investors, investments of up to a maximum of EUR 7.0 million per company are possible. 70% of the funding comes from the federal government through KfW and 30% from the Free and Hanseatic City of Hamburg. The fund is managed by IFB Innovationsstarter, a wholly owned subsidiary of Hamburgische Investments- und Förderbank. More information can be found at www.innovationsstarter.com.

About AI.FUND

AI.FUND is an AI-focused, entrepreneurial venture capital fund investing in Europe’s future AI leaders to promote impactful European-made AI. The fund invests in highly scalable, early-stage AI-based companies across a variety of vertical and horizontal sectors.

Communication

Mindpeak GmbH

Katja Eisele

E-mail: (email protected)